| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 503201 | 1 mg | $175 | ||
| 503202 | 5 mg | $480 | ||
| 503203 | 20 mg | $960 |
| Clone | Ifinatamab |
|---|---|
| Application | Flow cytometry, animal model study |
| Host Species | Mammalian cells |
| Format | Liquid |
| Product Description | Ifinatamab Biosimilar, Human B7-H3 Monoclonal Antibody |
| Isotype | Human IgG1 |
| Regulatory Status | RUO |
| Clonality | Recombinant |
| Immunogen | Human B7-H3 |
| Species specificity | Human |
| Purity | >95% by reducing SDS-PAGE |
| Grade | In vivo |
| Min Sample Size | 1 mg |
| Storage Conditions | 4ºC |
| Maximal Shelf Life | 12 months |
| Synonyms | CD276 |
| See All Formats | Clone Ifinatamab |
Ifanatamab, also known as Ifinatamab deruxtecan or DS-7300a, is a humanized monoclonal antibody belonging to the immunoglobulin G1 kappa (IgG1κ) subclass. It is engineered to recognize and bind to the human B7-H3 (CD276) cell surface glycoprotein, a member of the B7 family involved in immune regulation and intercellular signaling. As a therapeutic, the Ifanatamab molecule is part of an antibody–drug conjugate (ADC) system, where the IgG1 antibody is covalently linked to a cytotoxic topoisomerase I inhibitor, deruxtecan, via a cleavable peptide-based linker. The complete conjugate typically displays a molecular weight near 150 kilodaltons (kDa) and maintains the classical Y-shaped antibody configuration.
The antibody portion of Ifanatamab consists of two heavy chains and two light chains joined by disulfide bonds. The variable (VH and VL) domains form the antigen-binding regions, containing complementarity-determining regions (CDRs) that confer high specificity toward epitopes on the extracellular domains of B7-H3. The binding mechanism involves non-covalent interactions, including hydrogen bonds and hydrophobic contacts, ensuring nanomolar-level affinity. Upon binding to B7-H3 on the cell surface, the ADC-antigen complex undergoes receptor-mediated endocytosis, transporting the conjugate into the lysosomal compartment of the target cell.
The Fc (fragment crystallizable) region of the IgG1 backbone supports molecular stability and prolonged half-life by engaging neonatal Fc receptors (FcRn), while maintaining minimal immune effector activation.
Anti-Human B7-H3 (Ifinatamab Biosimilar) TDS
Have a product or application question? Consult our FAQs or contact us.
